CALA Overview
Upcoming Projects (CALA)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (CALA)
-
Examining the potential of Calithera’s advanced clear cell RCC therapy, telaglenastat (CB-839)
Ticker: CALA
Execute By: Apr 30, 2020
Upcoming & Overdue Catalysts (CALA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CALA)
-
Calithera Biosciences (CALA) Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
Ticker: CALA
Occurred on: Jan 04, 2021
Strategic Initiatives (CALA)
-
Bristol-Myers Squibb (BMY) Enters Collaboration Agreement with Calithera Biosciences (CALA) to Evaluating Opdivo + CB-839 in Clear Cell Renal Cell Carcinoma
Tickers: CALA, BMY
Announcement Date: Dec 21, 2016
